Investors included New York-listed drugs company Abbott Laboratories' corporate venturing subsidiary, Abbott Biotech Ventures.
US-based gene therapy company AuraSense Therapeutics raised an undisclosed amount in its series B round.
Investors included New York-listed drugs company Abbott Laboratories’ corporate venturing subsidiary, Abbott Biotech Ventures and angel investors Patrick Ryan, founder of insurer Aon, David Walt, co-founder of gene sequencer Illumina; Eric Schmidt, executive chairman of Google, and Craig Mundie, chief research and strategy officer at Microsoft. Thirty-nine investors provided $2.5m in the initial equity round in December 2009, according to a regulatory filing.
…
